𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon

✍ Scribed by Ridvan Ali; Fahir Ozkalemkas; Atilla Ozkan; Vildan Ozkocaman; Tulay Ozcelik; Ulku Ozan; Meral Kurt; Ahmet Tunali

Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
393 KB
Volume
31
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Neurotoxicity of bortezomib therapy in m
Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature
✍ Ashraf Badros; Olga Goloubeva; Jay S. Dalal; Ilyas Can; Jennifer Thompson; Aaron πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 95 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Bortezomib is active in heavily pretreated multiple myeloma patients; the dose‐limiting toxicity is peripheral neuropathy (PN). ## METHODS. The authors retrospectively reviewed the incidence, severity, and risk factors for PN in 78 patients who received bortezomib. The

Epidemiology of multiple myeloma in Taiw
Epidemiology of multiple myeloma in Taiwan : Increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years
✍ Shang-Yi Huang; Ming Yao; Jih-Luh Tang; Wen-Chung Lee; Woei Tsay; Ann-Li Cheng; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 195 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The incidence of multiple myeloma (MM) is lower in Asia than in western countries. However, no data are available on descriptive epidemiology of MM in Chinese. ## METHODS. From 1979 to 2003, 3602 MM patients were registered in the Taiwan National Cancer Registry. The a